| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.38968 |
| P698 | PubMed publication ID | 25417763 |
| P50 | author | Denis Poddubnyy | Q52876893 |
| Johanna Callhoff | Q60319589 | ||
| P2093 | author name string | Ulf Müller-Ladner | |
| Hildrun Haibel | |||
| Joachim Sieper | |||
| Uta Syrbe | |||
| Elena Neumann | |||
| Klaus W Frommer | |||
| Kristina Conrad | |||
| Susann Junker | |||
| P2860 | cites work | Adipokines in inflammation and metabolic disease | Q29620456 |
| Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. | Q33950766 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin | Q34493770 | ||
| Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans | Q35304374 | ||
| Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system | Q35554631 | ||
| Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum | Q35760141 | ||
| Adipose tissue, adipokines, and inflammation | Q36114223 | ||
| Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis | Q36148660 | ||
| Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis | Q36528874 | ||
| Developments in the scientific and clinical understanding of the spondyloarthritides | Q37207018 | ||
| Adiponectin and cardiovascular disease | Q37406647 | ||
| Can structural damage be prevented in ankylosing spondylitis? | Q37474294 | ||
| Innate immunity and adipose tissue biology | Q37740579 | ||
| Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases? | Q37845275 | ||
| Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis | Q37903553 | ||
| Adipocytes and the regulation of bone remodeling: a balancing act. | Q38150258 | ||
| Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. | Q38649096 | ||
| Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than | Q41201384 | ||
| Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities | Q42518164 | ||
| Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease | Q43825972 | ||
| The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort | Q44428886 | ||
| Elevated serum resistin in juvenile idiopathic arthritis: relation to categories and disease activity. | Q46149920 | ||
| Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. | Q46625159 | ||
| Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. | Q47751615 | ||
| Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. | Q49193647 | ||
| Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. | Q51503922 | ||
| Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. | Q52876799 | ||
| Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. | Q52895111 | ||
| Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. | Q54457120 | ||
| Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis | Q56957220 | ||
| P433 | issue | 3 | |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| P304 | page(s) | 678-685 | |
| P577 | publication date | 2015-03-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression | |
| P478 | volume | 67 |
| Q57623434 | A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis |
| Q38808869 | Adipokines in bone disease |
| Q47787817 | An update on biomarker discovery and use in axial spondyloarthritis |
| Q97421408 | An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision |
| Q64264615 | Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis |
| Q38681632 | Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis. |
| Q38680282 | Association of adipokines, interleukin-6, and tumor necrosis factor-α concentrations with clinical characteristics and presence of spinal syndesmophytes in patients with ankylosing spondylitis: A cross-sectional study |
| Q89495638 | Association of circulating resistin and adiponectin levels with Kawasaki disease: A meta-analysis |
| Q39098003 | Axial spondyloarthritis. |
| Q38762450 | Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study |
| Q96817691 | Biomarker development for axial spondyloarthritis |
| Q64120745 | Biomarkers for Diagnosis of Axial Spondyloarthritis, Disease Activity, Prognosis, and Prediction of Response to Therapy |
| Q35809286 | Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis |
| Q31146997 | Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry |
| Q40789778 | Characteristics of hip involvement in patients with ankylosing spondylitis in Korea |
| Q50025503 | Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis? |
| Q26778258 | Inflammation, bone loss and fracture risk in spondyloarthritis |
| Q26778275 | Obesity and inflammatory arthritis: impact on occurrence, disease characteristics and therapeutic response |
| Q38816459 | Pathogenesis of ligaments ossification in spondyloarthritis: insights and doubts |
| Q37358885 | Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles |
| Q41521787 | Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis: A preliminary 2-year longitudinal study |
| Q88930595 | Serum CCL11 level is associated with radiographic spinal damage in patients with ankylosing spondylitis |
| Q33801148 | Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial |
| Q28085617 | Syndesmophyte growth in ankylosing spondylitis |
Search more.